PEP-Therapy
French tech company | Builders Republic
About
Clinical-stage biotech developing cell-penetrating peptides as targeted cancer therapies — lead candidate PEP-010 targets pancreatic cancer and treatment-resistant ovarian adenocarcinoma, with FDA Orphan Drug Designation, in collaboration with Gustave Roussy and CNRS.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Extension
- Founded
- 2014
- City
- EVRY-COURCOURONNES
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 2.6 M€ raised since 2020
Funding rounds
- Extension — 2021
Investors
- Anaxago
- BADGE
- Fonds Unique Interministériel
- I&i Prague